MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617098797 A) filed by Bp Corporation North America Inc. on August 14, 2026, for Engineered Dxp Pathway For Improved Isoprenoid Production In E. Coli.
Inventors include Valle, Fernando; Tohidifar, Payman; Najdi, Tarek; and Vu, Huong Nguyen Nhu.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The present disclosure relates to recombinant microorganisms, such as bacteria, e.g., E. coli, engineered to have improved flux and/or yield of the DXP pathway. Cells can be engineered to comprise nucleotide sequences comprising dxs polypeptides (EC 2.2.1.7); dxr polypeptides (EC 1.1.1.267); ispD polypeptides (EC 2.7.7.60); ispE polypeptides (EC 2.7.1.148); ispF polypeptides (EC 4.6.1.12); ispG polypeptides (EC 1.17.7.1 or EC 1.17.7.3); ispH polypeptides (EC 1.17.7.4); and idi polypeptides (EC 5.3.3.2). Cells can be further engineered to express redox polypeptides, e.g., ferredoxins, flavodoxins, and/or flavodoxin/ferredoxin--NADP reductases (EC 1.19.1.1 or EC 1.18.1.2), e.g., to increase the activity of the ispG and/or ispH polypeptides. Some or all of the nucleotide sequences can be heterologous to the cells. The recombinant microorganisms can be used in methods of isoprenoid production.
Disclaimer: Curated by HT Syndication.
